BridgeMD
Zoledronate Early to Hip Fractures Patients – safe and effective? A Randomized controlled double-blinded treatment strategy trial on Zoledronate in hip fracture patients: The ZEBRA trial
EU CTIS ID: 2023-510198-32-00
What this study is testing
To have zoledronate within 5 days (early) after hip fracture surgery is non-inferior to have zoledronate 3 months (late) after hip fracture surgery measured by the level of bone suppression estimated by the bone turnover marker P1NP 12 months after zoledronate treatment.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- One low energy hip fracture
- Surgery within 72 hours
- >50 years old - Women age 50-60 must be postmenopausal or not pregnant
- Acceptable kidney function (estimated GFR >35) and calcium levels
- Fit to complete the follow-up judged by the recruiting physician
- Signed informed consent by the patient or the next of kin
You likely can't join if
- Metal in the opposite hip
- More than one acute fracture (concomitant fracture in addition to hip fracture)
- Anti-osteoporosis treatment with bisphosphonates, denosumab, teriparatid, abaloparatid or romosozumab within the last 10 years
- Glucocorticoid therapy, treatment with gnRH-analogs, aromatase-inhibitors, primary skeletal cancer or metastasis to the skeleton
- Too sick to receive treatment with zoledronate judged by the recruiting or treating physician
- Any other contraindication listed on the SmPC of the IMP(s) including pregnancy
See the full eligibility criteria
- One low energy hip fracture
- Surgery within 72 hours
- >50 years old - Women age 50-60 must be postmenopausal or not pregnant
- Acceptable kidney function (estimated GFR >35) and calcium levels
- Fit to complete the follow-up judged by the recruiting physician
- Signed informed consent by the patient or the next of kin
- Metal in the opposite hip
- More than one acute fracture (concomitant fracture in addition to hip fracture)
- Anti-osteoporosis treatment with bisphosphonates, denosumab, teriparatid, abaloparatid or romosozumab within the last 10 years
- Glucocorticoid therapy, treatment with gnRH-analogs, aromatase-inhibitors, primary skeletal cancer or metastasis to the skeleton
- Too sick to receive treatment with zoledronate judged by the recruiting or treating physician
- Any other contraindication listed on the SmPC of the IMP(s) including pregnancy
- Participating in another trial that might affect the current study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.